Commentary on a trial comparing krill oil versus fish oil

Lipids in Health and Disease

Mahinda Abeywardena²  Soressa M Kitessa¹  Peter D Nichols³ 

[1] CSIRO Animal, Foods and Health Sciences, Adelaide, South Australia, Australia;CSIRO Preventative Health Flagship Adelaide, Adelaide, South Australia, Australia;CSIRO Food Futures Flagship, Marine and Atmospheric Research, Hobart, TAS, Australia

关键词: Trial;    Fatty acids;    Fish oil;    Krill oil;   

Others  :  814736
DOI  :  10.1186/1476-511X-13-2

 received in 2013-12-24, accepted in 2013-12-26,  发布年份 2014

【 摘 要 】

Considerable interest exists presently in comparing the performance of krill oil (KO) and fish oil (FO) supplements. Ramprasath et al. (Lipids Health Dis12:178, 2013) have recently compared use of KO and FO in a trial with healthy individuals to examine which oil is more effective in increasing n-3 PUFA, decreasing the n-6:n-3 ratio and improving the omega-3 index. The authors concluded that KO was more effective than FO for all three criteria. However, careful examination of the fatty acid profiles of the oils used showed that the FO used was not a typical FO; it contained linoleic acid as the dominant fatty acid (32%) and an n-6:n-3 ratio of >1. Due to the fatty acid profile being non-representative of typically commercially marketed FO, the conclusions presented by Ramrasath et al. (Lipids Health Dis12:178, 2013) are not justified and misleading. Considerable care is needed in ensuring that such comparative trials do not use inappropriate ingredients.

【 授权许可】

   
2014 Nichols et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Ramprasath VR, Eyal I, Zchut S, Jones PJH: Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis 2013, 12:178. BioMed Central Full Text
• [2]Calder PC, Yaqoob P: Marine omega-3 fatty acids and coronary heart disease. Curr Opin Cardiol 2012, 27:412-419.
• [3]Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R: n-3 fatty acids in patients with multiple cardiovascular risk factors. New Engl J Med 2013, 368:1800-1808.
• [4]Proudman SM, Cleland LG, James MJ: Dietary omega-3 fats for treatment of inflammatory joint disease: Efficacy and utility. Rheum Dis Clin North Am 2008, 34:469-479.
• [5]Stall LA, Begg DP, Weisinger RS, Sinclair AJ: The role of omega-3 fatty acids in mood disorders. Curr Opin Investig Drugs 2008, 9:57-64.
• [6]Parletta N, Milte CM, Meyer BJ: Nutritional modulation of cognitive function and mental health. J Nutr Biochem 2013, 24:725-743.
• [7]Abeywardena MY, Patten GS: Role of ω3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors. Endocr Metab Immune Disord Drug Targets 2011, 11:232-246.
• [8]Winther B, Hoem N, Berge K, Reubaet L: Elucidation of phosphatidylcholine composition of krill oil extracted from Euphausia superb. Lipids 2011, 46:25-36.
• [9]Codabaccus BM, Carter CG, Bridle AR, Nichols PD: The “n-3 LC-PUFA sparing effect” of modified dietary n-3 LC-PUFA content and DHA to EPA ratio in Atlantic salmon smolt. Aquaculture 2012, 356–357:135-140.